A Single-Blind, Dose-Escalating Study to Assess Efficacy and Safety of Resiquimod Gel Applied 3 Times Per Week for up to 12 Weeks for the Treatment of Common Warts in Pediatric Subjects

Type of Study:

Interventional

Study Design:

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind, Primary Purpose: Treatment

Outcome Measure:

Clearance of treated common wart(s)

Authority:

United States: Food and Drug Administration

Study ID:

1534-RESI

NCT ID:

NCT00116662

Start Date:

March 2005

Completion Date:

Related Keywords:

• Warts
• Wart(s)
• Common Wart(s)
• Children
• Pediatric
• 3M Pharmaceuticals
• Resiquimod
• Warts